Figures & data
Table 1. Summary of TEM detection and importance in tumor development in different cancer types
Figure 1. Therapeutic approaches targeting human TEM. On the left in red, strategies reported in clinical trials, while proposed strategies are shown on the right in blue. Strategies aim at preventing the interaction of (1) TIE-2/ANG2 and/or (2) VEGF/VEGFR. (3) In BC, combined blockade of TIE-2 and VEGFR kinase activity induce reprogramming of TEM toward an antitumoral functional phenotype, whose effects are summarized in . Other approaches are based on (4) CD52-mediated TEM killing, (5) co-inhibition of CSFR-1 and VEGFR axes, (6) combined IL-10 and VEGF-A blockades. (7) VEGFR-1 function blocking antibodies impair the differentiation of CD34+ precursor cells into angiogenic TEM.
Figure 2. Effects of combined blockade of TIE-2 and VEGFR kinase activities on BC TEM. This treatment induces reprogramming of BC TEM toward an antitumoral functional phenotype enhancing tumor-specific T cell responses, dampens TEM pro-angiogenic and lymphangiogenic activities by decreasing their paracrine secretion of VEGFs, impairs TEM-mediated conversion of T cells into Tregs, impedes TEM paracrine secretion of the immunosuppressive cytokines IL-10 and VEGF-A and prevents TEM to interfere with DC maturation.
